Subcutaneous daratumumab: Ph Ib data

Data from 41 evaluable patients with relapsed or refractory MM in the dose-escalation part 1 of the open-label, international Phase Ib PAVO trial showed that once-weekly 1,200 and 1,800 mg doses of subcutaneous

Read the full 332 word article

User Sign In